Navigation Links
Coherus annonce que CHS-1420 (Adalimumab biosimilaire expérimental) est conforme aux critères d'efficacité principaux dans une étude clinique pharmacocinétique pivot
Date:8/15/2014

indre cette étape-jalon clinique valide encore plus la plate-forme de développement de Coherus et démontre notre capacité à développer des biosimilaires dans notre portefeuille », déclare Denny Lanfear, PDG de Coherus.

À propos de Coherus BioSciences, Inc.

Coherus est une entreprise plate-forme de médicaments biologiques de phase tardive centrée sur le marché biosimilaire mondial. Basée dans la région de la baie de San Francisco et composée par un groupe de vétérans de l'industrie avec des dizaines d'années d'expérience dans la création sociétés biologiques pionnières, Coherus a pour objectif de devenir un leader mondial du marché des biosimilaires en utilisant la somme des expertises de son équipe dans des domaines clés tels que la science des processus, la caractérisation analytique, la production de protéines et le développement clinique réglementaire. Les partenariats mondiaux de commercialisation de Coherus font intervenir des entreprises biopharmaceutiques mondiales en Europe, en Asie et en Amérique latine.

Les biosimilaires doivent remplacer les médicaments biologiques de marque actuels en vue de traiter une gamme élargie de maladies chroniques et mettant souvent en jeu le pronostic vital, avec le potentiel de réduire les coûts et de renforcer l'accès des patients. Pour de plus amples informations, veuillez consulter www.coherus.com.

Contact Coherus BioSciences 

Beth Jimison
+1-650-649-3526
bjimison@coherus.com

Logo - http://photos.prnewswire.com/prnh/20120507/SF01
'/>"/>

SOURCE Coherus BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coherus anuncia que CHS-1420 cumple con los objetivos primarios en el ensayo clínico farmacocinética pivote
2. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
3. Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
4. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
5. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
6. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
7. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
8. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
9. Annonce dun forum sur « La conception dappareils médicaux »
10. Blue Belt Technologies annonce que le Golden Jubilee National Hospital a réalisé la première opération NavioPFS darthroplastie unicondylaire du genou
11. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... SAN DIEGO , May 26, 2015 /PRNewswire/ ... in developing targeted therapeutic devices to address infectious ... A. Joyce , Chief Executive Officer, will present ... on Thursday, May 28th.  Details of Aethlon Medical,s ... Microcap Investor Conference Date: , Thursday, May 28, ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York City. The public is welcome to ... the Array BioPharma website.Event: Jefferies 2015 Global Healthcare ... p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array BioPharma ...
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
Breaking Medicine Technology:Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 2Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 4LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
... Carrot Medical, a leading manufacturer of integrated medical imaging display ... the year, Carrot Medical achieved significant growth in sales and ... half of 2011 with record second quarter sales, Carrot surpassed ...  The company is now well positioned for the third straight ...
... comedienne and TV favourite Jo Brand has joined forces with ... brand new comedy film (54 seconds) to launch Macmillan Cancer ... Jo Brand running around South London, in what looks like ... with Joanna Scanlan and produces a pint of milk; it ...
Cached Medicine Technology:Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
(Date:5/26/2015)... Carey Danis & Lowe provides ... . The suit pertains to AndroGel, a testosterone gel ... late April 2015, and a court document relating to ... in mid-May.¹ , Testosterone gel lawsuits are being consolidated ... of Illinois. The multidistrict litigation (MDL) is In Re: ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Degeneration of ... early marker of specific types of Alzheimer’s disease (AD), ... study published in the journal Radiology. , “Alzheimer’s ... Ph.D., co-author of the study conducted at the Neuroimaging ... “However, white matter damage has a central role in ...
(Date:5/26/2015)... MD (PRWEB) May 27, 2015 ... Order Contract (MATOC) by the United States Department of ... Center (PSC). The MATOC was awarded through ... Supply Schedule (FSS) for the PSC, which is a ... with four one year options, and is an enterprise–wide ...
(Date:5/26/2015)... The world of cosmetic plastic surgery ... to remain on the cutting edge of all new ... new additions to plastic surgery and his practice. There ... with emphasis on facelifts and mommy-makeovers all of which ... friendly and easy to navigate. The sites have a ...
(Date:5/26/2015)... May 26, 2015 Forex Income Boss ... in improving their results trading in the foreign exchange ... Russ Horn, utilizes 10 customer indicators to help traders ... , "As usual, Russ Horn's latest trading system is ... trading community," reports Tiffany Hendricks, senior product reviewer at ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Miguel Delgado, M.D. Launches Two New Plastic Surgery Websites 2Health News:Miguel Delgado, M.D. Launches Two New Plastic Surgery Websites 3Health News:Forex Income Boss - Review Of Russ Horn's New FX Trading System Released 2
... -- an antibiotic being prescribed to people who may ... growth when taken by pregnant women. Instead, the Centers ... Cipro to pregnant women. The recommendation comes as health ... general population, possibly causing common bacteria to become resistant ...
... study, a trial of a new anti-cancer drug interacts ... a natural product, is being tested as an anti-cancer treatment. ... of the drug on the genes that are activated in ... affected by ceflatonin. These experiments have been done in human ...
... advertisements of prescription drugs, statements about drug benefits ... quantify the medications' expected benefit; instead, they make ... Medical School, Hanover, New Hampshire. // ... is that the medicine is going to prevent ...
... warn that gout can be incredibly painful, and if not ... belief, gout can strike at any time, and for no ... rich food and wine, and women can be affected too, ... affect middle-aged men and some people find an attack follows ...
... pregnant women at risk of the potentially fatal condition ... and E. ,The study, published in the Lancet, found ... pre-eclampsia. ,The condition involves the pregnant mother with ... of the unborn child through the placenta. ,Between ...
... who snore when they are pregnant may be at risk ... lives when they give birth. Around 10% of pregnant women ... can lead to injury or even death in the mother ... pressure by resting or with medication. But drugs may put ...
Cached Medicine News:Health News:Snoring could be a warning 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Medicine Products: